الفهرس 
Effect of IL-12, IL-17 and IL-23 gene polymorphisms on the response of psoriatic patients to NB-UVB
AbstractOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Background: Psoriasis vulgaris is a genetic, systemic, inflammatory, chronic disorder to which Nb-UVB therapy offers a well-established treatment modality for psoriasis. Not all patients respond well to treatment, and some can develop severe adverse effects. Pharmacogenetics and pharmacogenomics can facilitate more personalized medicine and prevent the adverse effects associated with treatment . Objectives: to examine the effect of IL-12B p40; IL-17A and IL-23 A/G genes polymorphisms on the response of psoriatic patients to Nb-UVB. Patients and methods: The study was conducted on 100 psoriatic patients with surface area > 20%. 100 age and sex matched healthy volunteers were included in the study as a control group. Blood sample was taken from each patient. Genotyping of IL-12B p40; IL-17A G197A (rs2275913) and IL-23 A/G polymorphism at intron 9 (rs11465817) by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) technique. Patients took Nb-UVB three times weekly until improvement of baseline PASI by 75% (PASI 75) or for a maximum of 36 sessions. Results: Our study showed that patients expressing the 3 different genes polymorphisms were not associated with any different therapeutic response to Nb-UVB. However it was noted that IL-17A polymorphism and IL-23 A/G polymorphism were associated with more complications while IL-12 B p40 was not. Conclusion: further multicentral studies with larger sample sizes are needed in order to detect which pathway is more influencual amongst theories discussing the pathogenesis of psoriasis